Abstracts Archive - Page 2277 of 2425 - ACR Meeting Abstracts

Abstract Number: 2201 • 2012 ACR/ARHP Annual Meeting
Involvement of Interleukin-33 in the Pathogenesis of Sjögren’s Syndrome
Ahmad Awada, Valérie Gangji and Muhammad S. Soyfoo, Rheumatology, Hôpital Erasme,Université Libre de Bruxelles, Brussels, Belgium
Background/Purpose: To investigate the role of IL-33/ST2 in the pathophysiology of primary Sjögren’s syndrome (pSS) Methods: Serum levels of IL-33 and sST2 was determined by…
Abstract Number: 2162 • 2012 ACR/ARHP Annual Meeting
Correlation of A Multi-Biomarker Disease Activity (VECTRA™ DA) Score with Clinical Disease Activity and Its Components with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Tofacitinib
Kunihiro Yamaoka¹, Satoshi Kubo¹, Koshiro Sonomoto¹, Shintaro Hirata¹, Guy Cavet², Rebecca Bolce², Michael W. Rowe², David Chernoff², Nadine Defranoux², Kazuyoshi Saito¹ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: A multi-biomarker disease activity (MBDA) score has been developed for evaluation of disease activity of rheumatoid arthritis (RA) to complement clinical assessment and to…
Abstract Number: 2163 • 2012 ACR/ARHP Annual Meeting
Abatacept Monotherapy Effectively Reduces the Frequency of Osteoclast Precursor Cells in the Peripheral Blood of Patients with Rheumatoid Arthritis and Inhibits Their Differentiation Into Osteoclasts
Sandra Mueller-Schmucker¹, Roland Axmann¹, Sonja Herman², Mario Zaiss¹, Manuela Le Bars³, Thomas Harrer¹ and Georg A. Schett⁴, ¹University of Erlangen-Nuremberg, Erlangen, Germany, ²Rheumatology, Medical University of Vienna, Vienna, Austria, ³Bristol-Myers Squibb, Rueil Malmaison, France, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Bone resorbing osteoclasts origin from monocytes. We have recently shown that binding of abatacept (CTLA4-Ig) to CD80 and CD86 on the surface of monocytes…
Abstract Number: 2164 • 2012 ACR/ARHP Annual Meeting
Evidence for NF-Kb Intracellular Signaling Involvement Following CTLA4-Ig (Abatacept) Treatment of Human Macrophages
Renata Brizzolara¹, Paola Montagna¹, Stefano Soldano², Alberto Sulli³, Bruno Seriolo⁴, Barbara Villaggio⁵, Pierfranco Triolo⁶, Lamberto Felli⁷ and Maurizio Cutolo⁸, ¹Department of Internal Medicine, Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ³Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁵Research Laboratory of Nephrology, Department of Internal Medicine, University of Genova, Genova, Italy, ⁶Rheumatoid Arthritis Unit, Orthopedic Surgery Department, CTO Hospital, Turin, taly, Turin, Italy, ⁷Orthopedic Department, University of Genova, Genova, Italy, ⁸Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy
Background/Purpose: The transcription factor NF-kB is an intracellular signaling essential for the expression of a variety of immune-response genes, including those related to pro-inflammatory cytokines…
Abstract Number: 2165 • 2012 ACR/ARHP Annual Meeting
Utility of Vectra-DA™ On Assessment of Rheumatoid Arthritis Disease Activity and Golimumab Response: Results of a Pilot Study From a Phase 3 Trial in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy
Sarah Lamberth, Yauheniya Cherkas, Carrie Brodmerkel and Mark Curran, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: Currently, disease activity in Rheumatoid Arthritis (RA) is measured using scoring systems that rely primarily on a collection of subjective measures from patients and…
Abstract Number: 2166 • 2012 ACR/ARHP Annual Meeting
Identification of Serological Biomarker Profiles Associated with Response to IL-6 Intervention in Rheumatoid Arthritis
Morten Asser Karsdal¹, Anne C. Bay-Jensen², Inger Byrjalsen³, Andrew Kenwright⁴, Adam Platt⁴, Thierry Sornasse⁵ and Claus Christiansen⁶, ¹Nordic Bioscience A/S, Herlev, Denmark, ²Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ³Research & Development, Nordic Bioscience, Herlev, Denmark, ⁴Roche, Welwyn Garden City, United Kingdom, ⁵Product Development Immunology, Genentech, Inc., South San Francisco, USA, San Fransisco, CA, ⁶CCBR, Ballerup, Denmark
Background/Purpose: RA is characterized by poly-articular synovial inflammation, cartilage loss and erosion of subchondral bone. It is critical to diagnose and effectively treat the disease…
Abstract Number: 2167 • 2012 ACR/ARHP Annual Meeting
Serum Based Biomarkers of Joint Destruction Can Identify Responders and Non-Responder to Tocilizumab
Anne C. Bay-Jensen¹, Inger Byrjalsen², Claus Christiansen³ and Morten Asser Karsdal⁴, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Research & Development, Nordic Bioscience, Herlev, Denmark, ³CCBR, Ballerup, Denmark, ⁴Nordic Bioscience A/S, Herlev, Denmark
Background/Purpose: RA is characterized by synovial inflammation, cartilage loss and erosion of subchondral bone. It is critical to diagnose and effectively treat the disease early…
Abstract Number: 2168 • 2012 ACR/ARHP Annual Meeting
Tolerance and Efficacy of Rituximab in Elderly Patients with Rheumatoid Arthritis Enrolled in the French Society of Rheumatology Air Registry
Sarah Payet¹, Jacques-Eric Gottenberg², Xavier Mariette³, Philippe Ravaud⁴, Elodie Perrodeau⁵, Thomas Bardin⁶, Patrice Cacoub⁷, Alain G. Cantagrel⁸, Bernard Combe⁹, Maxime Dougados¹⁰, Rene-Marc Flipo¹¹, Bertrand Godeau¹², Loic Guillevin¹³, Xavier X. Le Loet¹⁴, Eric Hachulla¹⁵, Thierry Schaeverbeke¹⁶, Jean Sibilia¹⁷, Isabelle Pane¹⁸, Gabriel Baron¹⁹ and Martin Soubrier²⁰, ¹Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ²Rheumatology, Strasbourg University Hospital, Strasbourg, France, ³Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ⁴Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁵Epidemiologist, Paris, France, ⁶Rheumatology, Hôpital Lariboisière, Paris, France, ⁷Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁸Dept of Rheumatology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ⁹Rheumatology, Hopital Lapeyronie, Montpellier, France, ¹⁰Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ¹¹Rheumatology, Hopital R Salengro CHRU, Lille, France, ¹²Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, ¹³Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ¹⁴Rheumatology Department, CHU de ROUEN, Rouen, France, ¹⁵Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹⁶Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ¹⁷Université de Strasbourg, EA4438 Laboratoire Physiopathologie des Arthrites, Illkirch-Strasbourg, France, ¹⁸Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹⁹Hotel Dieu University Hospital Paris, Epidemiology, Paris, France, ²⁰Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France
Background/Purpose: This study aimed to compare the efficacy and the safety of Rituximab (RTX)in elderly (aged ≥ 65years) and younger patients (aged 18-64 years) with…
Abstract Number: 2169 • 2012 ACR/ARHP Annual Meeting
Short to Medium Term Safety of Glucocorticoid Therapy in Rheumatoid Arthritis: A Systematic Review and Dose-Response Analysis of Randomized Controlled Trials
Simon Tarp¹, Daniel Furst², John R. Kirwan³, Maarten Boers⁴, Henning Bliddal⁵, Thasia Woodworth⁶, Else Marie Bartels⁷, Bente Danneskiold-Samsoe⁵, Lars Erik Kristensen⁸, Steffen Thirstrup⁹, Mette Rasmussen⁹, Marian Kaldas¹⁰ and Robin Christensen¹, ¹Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ²Div of Rheumatology, UCLA Medical School, Los Angeles, CA, ³Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom, ⁴Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ⁵Department of Rheumatology, The Parker Institute, Copenhagen University Hospital at Frederiksberg, Copenhagen F, Denmark, ⁶Leading Edge Clinical Research LLC, Florida, FL, ⁷Department of Rheumatology, The Parker Institute, Copenhagen University Hospital at Bispebjerg and Frederiksberg, Copenhagen F, Denmark, ⁸Rheumatology, Skåen University Hospital, Lund University, Lund, Sweden, ⁹Institute for Pharmacology and Pharmacotherapy, University of Copenhagen, Copenhagen, Denmark, ¹⁰David Geffen School of Medicine, University of California in Los Angeles, Los Angeles, CA
Background/Purpose: Concerns regarding Adverse Effects (AEs) often dominate decisions on applying Glucocorticoid (GC) therapy. Evidence of AEs is mainly based on observational data without proper…
Abstract Number: 2170 • 2012 ACR/ARHP Annual Meeting
Methotrexate and Interstitial Lung Disease in Rheumatoid Arthritis – A Systematic Literature Review and Meta-Analysis
Richard Conway¹, Candice Low², Robert J. Coughlan³, Martin O'Donnell⁴ and John J. Carey³, ¹Rheumatology, St James's Hospital, Dublin, Ireland, ²Medicine, St. James Hospital, Dublin, Ireland, ³Rheumatology, Galway University Hospitals, Galway, Ireland, ⁴Clinical Research Facility, Galway University Hospitals, Galway, Ireland
Background/Purpose: Methotrexate is commonly prescribed for a variety of diseases including rheumatoid arthritis. Methotrexate has frequently been implicated as a causative agent in interstitial lung…
Abstract Number: 2171 • 2012 ACR/ARHP Annual Meeting
Comparative Efficacy of Biologics As Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with an Inadequate Response to Conventional Dmards: A Network Meta-Analysis
Felicity Buckley¹, Axel Finckh², Thomas W. Huizinga³, Fred Dejonckheere⁴ and Jeroen P. Jansen¹, ¹MAPI Consultancy, Boston, MA, ²Rhumatology, University Hospital of Geneva, Geneva, Switzerland, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: A number of meta-analyses compare the efficacy of biologics for rheumatoid arthritis (RA). However, systematic reviews comparing the efficacy of biologics as monotherapy versus…
Abstract Number: 2172 • 2012 ACR/ARHP Annual Meeting
An Update of Management of Coccidioidomycosis in Patients On Biologic Response Modifiers and Disease-Modifying Antirheumatic Drugs
Susan Knowles¹, Dominick Sudano¹, Sara Taroumian², Neil M. Ampel³, John Galgiani⁴, Jeffrey R. Lisse¹ and Susan E. Hoover⁵, ¹Department of Rheumatology, University of Arizona, Tucson, AZ, ²Department of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ³Infectious Disease, University of Arizona, Tucson, AZ, ⁴Valley Fever Center for Excellence, Tucson, AZ, ⁵Infectious Diseases, University of Arizona, Tucson, AZ
Background/Purpose: Coccidioidomycosis (valley fever) is an endemic fungal infection in the Southwestern United States which typically causes a self-limited pulmonary illness. Patients with rheumatic disease…
Abstract Number: 2173 • 2012 ACR/ARHP Annual Meeting
Pharmacoeconomic Evaluation of Tocilizumab Monotherapy Vs. Adalimumab Monotherapy in Reducing Disease Activity in Patients with Rheumatoid Arthritis
Navarro Sarabia F¹, Francisco J. Blanco V², Álvaro Gracia JM³, JA García Meijide⁴ and Jl Poveda⁵, ¹Rheumatologist Service, Hospital. Virgen Macarena, Sevilla, Spain, ²Rheumatology Service, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ³Rheumatology Service, H. Universitario La Princesa, Madrid, SC, Spain, ⁴Rheumatologist Service, Hospital Ntra. Sra. La Esperanza, Santiago de Compostela, Spain, ⁵Pharmacy Service, Hospital Universitario La Fe, Valencia, Spain
Background/Purpose: ADACTA trial (Gabay C et al EULAR June 2012) showed that tocilizumab (TCZ) monotherapy was superior to adalimumab (ADA) monotherapy in reducing signs and…
Abstract Number: 2174 • 2012 ACR/ARHP Annual Meeting
Natural History of Sjögren’s Syndrome Phenotypic Features in the Sjögren’s International Collaborative Clinical Alliance Registry
Caroline Shiboski¹, Alan N. Baer², Mi Y. Lam¹, Stephen Challacombe³, Hector Lanfranchi⁴, Morten Schiødt⁵, Hisanori Umehara⁶, Frederick B. Vivino⁷, Yan Zhao⁸, Yi Dong⁸, Bruce W. Kirkham⁹, Kenneth E. Sack¹⁰, Susumu Sugai¹¹, Cristina F. Vollenweider¹², Wen Zhang⁸, John S. Greenspan¹, Troy Daniels¹³, Lindsey A. Criswell¹⁴ and Sjögren's International Collaborative Clinical Alliance¹⁵, ¹Orofacial Sciences, University of California San Francisco, San Francisco, CA, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Kings College London, London, United Kingdom, ⁴University of Buenos Aires, Buenos Aires, Argentina, ⁵Oral and Maxillofacial Surgery, Rigshospitalet, Copenhagen, Denmark, ⁶Internal Medicine, Division of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan, ⁷Medicine, Penn Presbyt Med Ctr, Philadelphia, PA, ⁸Rheumatology, PUMCH, Bejing, China, ⁹Rheum Dept/ Guys Hospital, Guys Hospital, London, United Kingdom, ¹⁰Dept of Medicine/Box0326, Univ of Calif-San Francisco, San Francisco, CA, ¹¹Kanazawa Medical University, Ishikawa, Japan, ¹²Rheumatology, German Hospital, Buenos Aires, Argentina, ¹³Orofacial Sciences, Box 0422, University of California San Francisco, San Francisco, CA, ¹⁴Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ¹⁵Orofacial Sciences, University of California San Francisco, University of California San Francisco, CA
Background/Purpose: Sjögren’s syndrome (SS) is known to be a relatively stable or slowly progressing disease, however, few studies have actually followed patients over time while…
Abstract Number: 2175 • 2012 ACR/ARHP Annual Meeting
Interstitial Lung Disease in Sjogren Syndrome: A Population-Based Study
Carlotta Nannini¹, Adlene Jebakumar², Jay H. Ryu³, Cynthia S. Crowson⁴ and Eric L. Matteson², ¹Rheumatology Unit, Prato Hospital, Prato, Italy, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ⁴Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: The reported frequency of pulmonary involvement in primary Sjögren’s Syndrome (pSS) varies widely ranging from 8 to 75% depending on the detection method employed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].